AMD eye drops trial kicks off

TareGen has initiated a multicentre Phase II clinical trial for the topically applied TG100801 in patients with age-related macular degeneration (AMD).

TareGen has initiated a multicentre Phase II clinical trial for the topically applied TG100801 in patients with age-related macular degeneration (AMD).

TG100801 is administered non-invasively as an eye drop and has been developed to suppress VEGF-mediated leakage and additional kinase targets associated with inflammation, oedema and angiogenesis.

A second topically applied compound for eye disease, TG100948, is also in early development.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Related Content
© 2023 MJH Life Sciences

All rights reserved.